Office of Technology Commercialization

Expediting Form - Material Transfer Agreement (MTA)

UT Health SA is Providing Materials

This is NOT a Material Transfer Agreement or an offer of any kind. ***This form must be completed and processed before an MTA is prepared.***

Providing Scientist: Click here to enter text. Department: Click here to enter text.

Phone: Click here to enter text. Building/Room No.: Click here to enter text. E-mail: Click here to enter text.

MATERIALS Requested (MATERIAL) Click here to enter text.

Name of Institution/Company requesting MATERIALS (RECIPIENT) Click here to enter text.

Address of Institution (RECIPIENT Address)Click here to enter text.

Recipient Contact Name: Click here to enter text. Phone: Click here to enter text. Email: Click here to enter text.

Person Conducting Research/Study: Click here to enter text. Phone: Click here to enter text. Email: Click here to enter text.

Describe the MATERIAL in layman’s terms:

Click here to enter text.

Describe RECIPIENT’S intended use of the MATERIAL (RESEARCH PLAN): Click here to enter text.

Proposed time period for RECIPIENT’S use and possession of MATERIAL: Click here to enter text.

Is the transfer of MATERIAL part of a collaboration? [ ] No [ ] Yes

If Yes, do you have a written agreement describing the collaboration? [ ] No [ ] Yes

Was the MATERIAL developed solely in your lab at UTHSCSA? [ ] No [ ] Yes

If No, where was it developed and by whom?

Click here to enter text.

Was the MATERIAL originally obtained from another firm, institution or colleague? [ ] No [ ] Yes

If Yes, who was the original provider? Click here to enter text.

Does the MATERIAL contain or was it derived from material(s) received from others?(repositories, gifts, MTAs) [ ] No [ ] Yes

If Yes, what are the other material(s) and providers? Click here to enter text.

Does the MATERIAL incorporate GFP or TET technology?

 [ ] No [ ] Yes

If Yes, which one(s) and who was the provider / source? Click here to enter text.

\*\*DuPont OncoMouse® Technology

Mouse spontaneously develops cancer?

No [ ]  Yes [ ]

Crossbred progeny develops cancer?

No [ ]  Yes [ ]

Knock-In?

No [ ]  Yes [ ]

Knock-out?

No [ ]  Yes [ ]

Conditional transgenic model?

No [ ]  Yes [ ]

What source(s) of funding was used to develop MATERIAL?

[ ] NIH

[ ] FDN

[ ] Dept./Start-up

PGID #Click here to enter text.

Has a description of MATERIAL been published?

[ ] No [ ] Yes

 If Yes, where and when (citation) Click here to enter text.

Are you the only source for MATERIAL?

[ ] No [ ] Yes [ ] Not sure

If No, who else is a source for MATERIAL? Click here to enter text.

Has the MATERIAL been disclosed to OTC as an invention? [ ] No [ ] Yes

If Yes, OTC file number: Click here to enter text.

Will RECIPIENT be producing any progeny or unmodified derivatives from MATERIAL?

[ ] No [ ] Yes [ ] Not sure

Do you want a copy of the research results from RECIPIENT? [ ] No [ ] Yes

Do you want to review RECIPIENT’S findings prior to publication? [ ] No [ ] Yes

Do you want to be acknowledged in RECIPIENT’S publication(s)? [ ] No [ ] Yes

Do you wish to be reimbursed by RECIPIENT for the cost of the MATERIAL? [ ]  No [ ]  Yes

If Yes, please provide cost and account number

costs were encumbered from Click here to enter text.

Do you want RECIPIENT to return or destroy any remaining MATERIAL, progeny and unmodified derivatives after completing RESEARCH PLAN?

[ ] Return [ ] Destroy

Likelihood of an invention resulting from RECIPIENT’S use of the MATERIAL?

[ ] Highly possible

[ ] Somewhat possible

[ ] Not expected

Is the MATERIAL a select agent or toxin as defined by the federal government? See [www.cdc.gov/od/sap/docs/salist.pdf](http://www.cdc.gov/od/sap/docs/salist.pdf) for a list of select agents and toxins. [ ] No [ ] Yes

 If Yes, please describe Click here to enter text.

FOR HUMAN MATERIALS ONLY:

**HUMAN BIOLOGICAL MATERIALS REQUESTED** (MATERIAL): [Describe]

**PROVIDER IRB APPROVAL:** Human tissues or samples must be collected with Provider Institution’s IRB approved Protocol or exemption. All human Materials must be de-identified by Provider.

**Title of IRB approved Protocol**  **IRB number**  **Exemption**

(**Attach copy of IRB approval or exemption letter and letter from Tissue Bank Manager approving transfer**.)

### **Is the Material and any data related to the Material de-identified?** [ ]  No [ ]  Yes

**Was the Material originally obtained from a repository or catalog?** [ ]  No [ ]  Yes

To the best of my knowledge, the above information is true and correct. I hereby certify that there are no existing agreements that would limit the use of the MATERIAL or prohibit or limit distribution or transfer of the MATERIAL to other entities, whether they be commercial, private, or otherwise.

Signature:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date:Click here to enter a date.

When you have completed all fields in this form, please sign, date, and email a copy to the attention of the Intellectual Property Manager at disclosures@uthscsa.edu.

**DEFINITIONS**

**Progeny**: Unmodified descendant from the MATERIAL, such as virus from virus, cell from cell, or organism from organism.

**Unmodified Derivatives**: Substances created by the RECIPIENT which constitute an unmodified functional subunit or product expressed by the MATERIAL. Some examples include: subclones of unmodified cell lines, purified or fractionated subsets of the MATERIAL, proteins expressed by DNA/RNA supplied by the PROVIDER, or monoclonal antibodies secreted by a hybridoma cell line.